Thwarting galectin-induced immunosuppression in breast cancer

Mariana Salatino Laboratorio de Inmunopatología; Instituto de Biología y Medicina Experimental (IBYME-CONICET); Buenos Aires, ArgentinaCorrespondence[email protected]

Tomas Dalotto-Moreno Laboratorio de Inmunopatología; Instituto de Biología y Medicina Experimental (IBYME-CONICET); Buenos Aires, Argentina

Gabriel A. Rabinovich Laboratorio de Inmunopatología; Instituto de Biología y Medicina Experimental (IBYME-CONICET); Buenos Aires, Argentina

Abstract

Novel therapeutic strategies are needed to counteract breast cancer-associated immunosuppression. Silencing the expression of galectin-1 in a breast carcinoma model inhibited tumor growth and prevented lung metastasis by reducing the frequency and immunosuppressive activity of CD4⁺CD25⁺ FOXP3⁺ regulatory T cells.

Keywords: :

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Thwarting galectin-induced immunosuppression in breast cancer

Information for

Open access

Opportunities

Help and information

Thwarting galectin-induced immunosuppression in breast cancer

Abstract

Disclosure of Potential Conflicts of Interest

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature